HIV / AIDS in the News

Dr Reddy’s Hetero ties up with Gilead Sciences for anti-HIV drug Lenacapavir - BusinessLine

 

Gilead agrees to license new HIV drug in low-income countries - BioPharma Dive

 

Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug - Business Standard

 

Hetero inks voluntary licensing pact with Gilead for HIV drug lenacapavir - CNBCTV18

 

Dr Reddy's inks licensing pact with Gilead to commercialise HIV drug - CNBCTV18

 

Dr Reddy's enters voluntary licensing deal with Gilead for long-acting HIV drug - economictimes.com

 

US’s $100 Billion HIV Program Commits to African Manufacturing - Bloomberg

 

US’s $100 Billion HIV Program Commits to African Manufacturing - Bloomberg Law

 

Dr Reddy's inks Licensing Pact with Gilead to Commercialise HIV Drug - Bizz Buzz

 

Dr. Reddy’s Expands Access to HIV Treatment - TipRanks

 

Gilead strikes deal to rush HIV prevention drug to countries most in need - The Business Journals

 

Dr Reddy's ties up with Gilead to manufacture, commercialise HIV drug - Business Standard

 

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries - PR Newswire

 

Results from a Phase I clinical trial of a dendritic cell - GlobeNewswire

 

Takeaways From AP's Report on Declining Condom Use Among Younger Generations - U.S. News & World Report

 

Pharmalittle: We're reading about a Blue Cross California deal for Humira, Gilead licensing an HIV drug, and more - STAT

 

Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug - STAT

 

Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug - STAT

 

Gilead Licenses Long-Acting HIV Prevention Drug to Generics Firms - Bloomberg

 

Gilead Sciences (GILD) Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countri - StreetInsider.com

 

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries - Business Wire

 

Rise in HIV diagnoses shows need for 10-year sexual health strategy – LGA on new HIV figures - Local Government Association

 

HIV incidence and its associated factors among young adults with multiple sexual partners in Maputo, Mozambique: a vaccine preparedness study - BMC Public Health

 

Migration fuels surge in HIV cases by 50 per cent in a year to reach a 15-year high, official report finds - Daily Mail

 

National Latinx AIDS Awareness Day - HIV.gov

 

Defining the Goals of HIV Science Through 2034 - HIV.gov

 

Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries - Reuters

 

South Africa: Couple Receives Prestigious Award for HIV/AIDS Work - South African News Briefs - October 2, 2024 - AllAfrica - Top Africa News

 

Cempa Community Care launches initiative to tackle HIV in homeless communities - Chattanooga Times Free Press

 

R.I.P. Author Tom Spanbauer, Who Wrote of Gay Life, Family and HIV - POZ